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Abstract
Background:  Acute pancreatitis is a common complication of endoscopic retrograde
cholangiopancreatography and benefit of pharmacological treatment is unclear. Although
prophylactic use of corticosteroid for reduction of pancreatic injury after ERCP has been evaluated,
discrepancy about beneficial effect of corticosteroid on pancreatic injury still exists. The aim of
current study is to evaluate effectiveness and safety of corticosteroid in prophylaxis of post-
endoscopic retrograde cholangiopancreatography pancreatitis (PEP).
Methods: We employed the method recommended by the Cochrane Collaboration to perform
a meta-analysis of seven randomized controlled trials (RCTs) of corticosteroid in prevention of
post-ERCP pancreatitis (PEP) around the world.
Results: Most of the seven RCTs were of high quality. When the RCTs were analyzed, odds ratios
(OR) for corticosteroid were 1.13 [95% CI (0.89~1.44), p = 0.32] for PEP, 1.61 [95% CI
(0.74~3.52), p = 0.23] for severe PEP, 0.92 [95% CI (0.57~1.48), p = 0.73] for post-ERCP
hyperamylasemia respectively. The results indicated that there were no beneficial effects of
corticosteroid on acute pancreatitis and hyperamylasemia. No evidence of publication bias was
found.
Conclusion: Corticosteroids cannot prevent pancreatic injury after ERCP. Therefore, their use in
the prophylaxis of PEP is not recommended.
Background
ERCP is one of the important procedures for diagnosis
and treatment of several biliary and pancreatic conditions.
However, ERCP can also cause acute pancreatitis and
result in significant morbidity and mortality [1,2].
Depending on the definition, it has been reported that
incidence of post-ERCP pancreatitis (PEP) was 1% to 40%
of cases, whereas post-operative hyperamylasemia can be
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up to 70% of cases [3]. Although most cases of PEP were
mild, about 10% of them were severe pancreatitis [4],
which could result in prolonged stay in hospitals and
increase risk to patients' life.
There were numerous attempts to minimize occurrence
and severity of PEP. However most of them were disap-
pointed. Prevention of PEP with calcitonin, aprotonin,
nifedipine and glucagon did not show any decrease in
post-ERCP hyperamylasemia or pancreatitis [5-8]. Moreo-
ver, a few studies with long-acting somatostatin analogue
– octreotide produced conflicting results [9-12]. Further-
more, a recent meta-analysis of all prospective rand-
omized clinical trials (RCTs) of protease inhibitor –
gabexate mesilate concluded that gabexate mesilate can-
not prevent the pancreatic injury after ERCP [13].
Corticosteroid is an anti-inflammatory hormone and is
able to ameliorate injury response. It has been shown that
corticosteroid is able to increase activity of C1-antipro-
tease inhibitor [14], decrease synthesis of phospholipase
A2 [15], and suppress cellular and humoral responses.
Since acute pancreatitis is a process of autodigestion char-
acterized by release of activated pancreatic enzymes [16],
corticosteroid may reduce inflammatory response during
initial steps of autodigestive cascade. Therefore, one large
retrospective and 7 prospective studies of corticosteroid in
prophylaxis of PEP have been conducted recently [17-24].
However, these studies could not reach a clear conclusion
about beneficial effects of corticosteroid on prophylaxis of
PEP. Therefore, it will be necessary to conduct a meta-
analysis of all available RCTs to reveal use of corticoster-
oid in prophylaxis of PEP.
Methods
Selection criteria
We searched different databases, which included the
Cochrane Controlled Trials Register on The Cochrane
Library Issue 2, 2007, MEDLINE (January, 1966 – June,
2007), EMBASE.com (January, 1966 – June, 2007) and
the China Biological Medicine Datadase (CBMdisc) (Jan-
uary, 1978 – June, 2007) by the terms of pancreatitis,
ERCP, prevent*, corticosteroid, prednisone, PEP. The refer-
ence lists of pertinent reviews and retrieved articles had
been checked for additional study identification.
In the meta-analysis, the following inclusive selection cri-
teria were set and reviewed by two independent investiga-
tors: (1) each trial should be a prospective randomized
controlled clinical trial, (2) the age of patient population
should be over 18 years, (3) the patients were scheduled
to undergo ERCP and/or endoscopic sphincterotomy, (4)
randomized comparisons of corticosteroid versus placebo
should be included regardless of initial time of treatment,
treatment duration, dose and administration route of
drug, (5) co-interventions (including treatment of com-
plications) were allowed if administered equally to all
intervention groups. The following exclusive selection cri-
teria were set: (1) quasi-randomized trials and non-rand-
omized studies, (2) active acute pancreatitis, (3)
difference of co-interventions between intervention arms,
(4) repetitive reports (if more than one version of the
same study was retrieved, only the most recent one was
used).
A total of 15 clinical trials and reports has been identified
and only seven trials [18-24] were qualified by our selec-
tion criteria (Figure 1). Four out of seven studies included
patients submitted only to diagnostic ERCP and three to
diagnostic and therapeutic ERCP. All of the studies
adopted the PEP diagnostic criteria that Cotton et al. [3]
proposed in 1991 and a severe PEP was reported in five
studies. Five out of seven RCTs were adequate in the allo-
cation concealment judgment and two were unclear. The
studies were independently evaluated by two of us with
five outcomes, which included three primary outcomes
(PEP, severe PEP and case-fatality ratio of PEP) and two
secondary outcomes (post-ERCP hyperamylasemia and
abdominal pain). Discrepancies in the evaluation of some
studies were resolved through discussion between the
reviewers. Main features of the trials included in meta-
analysis are shown in Table 1.
Assessment of study quality
Quality of included reports was scored using the Jadad
composite scale [25], which assesses descriptions of rand-
omization, blinding, and dropouts (withdrawals) in
reports [26]. The quality scale ranges from 0 to 5 points
with a low-quality report of score at 2 or less and a high-
quality report of score at least 3 [27].
Statistical analysis
The meta-analysis was carried out by a biostatistician
(Jianling Bai) according to the Cochrane Reviewers'
Handbook recommended by The Cochrane Collabora-
tion. Pooled odds ratio (OR) was calculated using the gen-
eral inverse variance (IV) fixed-effect model. The
heterogeneity between studies was examined by DL Q sta-
tistic [28]. If results were heterogeneous (p < 0.05), a ran-
dom-effects model was employed using the DerSimonian
and Laird (DL) methods. For studies in which the con-
structed 2×2 tables contained cells with zero events, a
standard correction factor of 0.5 was added to each cell.
Pooled OR was presented as standard plots with 95 per-
cent confidence intervals (CI). Publication bias was meas-
ured by Begg and Mazumdar's proposed adjusted rank
correlation test [29] and Egger's linear regression
approach [30], and was shown as a funnel plot. Sensitiv-
ity-analysis was also performed to assess the reliability of
meta-analysis. The statistical package RevMan version 4.2BMC Gastroenterology 2008, 8:6 http://www.biomedcentral.com/1471-230X/8/6
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(provided by The Cochrane Collaboration, Oxford, Eng-
land) was used for statistical analysis.
Results
Primary outcome
In this report, we considered PEP as the primary outcome
which was divided into general PEP and severe PEP. The
report of general PEP was noticed in all seven RCTs [18-
24]. These trials included 2632 patients with 299 patients
suffering from PEP. Among PEP-suffering patients, 157
(12.0%) patients were treated with corticosteroid whereas
142 (10.8%) patients were treated with placebo. There
was no significant heterogeneity among these studies (χ2
= 8.56, 6 degrees of freedom, p = 0.20). However, analysis
Table 1: Randomized controlled trials on the use of corticosteroid for the prevention of pancreatic injury after ERCP
Author and publication 
year
Setting Jadad score Sample size Type of corticosteroid 
administration
Dosage (mg) Duration
Budzynska, 1997 Poland single centre 1 184 Prednisone, orally 40 15 hours and 3 hours 
before ERCP
Dumot, 1998 United States 
multicentre
4 255 Methylprednisolone, 
intravenous bolus
125 15 to 30 minutes before 
ERCP
De Palma, 1999 Italy single centre 5 529 Hydrocortisone, intravenous 
infusion
100 Immediately before 
ERCP
Budzynska, 2001 Poland single centre 2 201 Prednisone, orally 40 15 hours and 3 hours 
before ERCP
Manolakopoulos, 2002 Greece multicentre 5 228 Hydrocortisone, intravenous 
infusion
100 30 minutes before 
ERCP
Sherman, 2003 United States 
multicentre
4 1115 Prednisone, orally 40 15 hours and 3 hours 
before ERCP
Kwanngern, 2005 Thailand single 
centre
4 120 Hydrocortisone, intravenous 
infusion
100 1 hour before ERCP
Identification of eligible randomized controlled trials from different medicine databases Figure 1
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by a fixed-effects model indicated an IV fixed-effect
pooled OR = 1.13 [(95 percent CI 0.89 to 1.44); p = 0.32]
with no significant association between the use of corti-
costeroid and the reduction of PEP (Figure 2, Table 2).
When stratified by setting, there was no significant reduc-
tion of PEP in either single centre studies (IV fixed-effect
pooled OR = 1.04 [(95 percent CI 0.66 to 1.64); p = 0.87])
or multicentre studies (IV fixed-effect pooled OR = 1.17
[(95 percent CI 0.88 to 1.56); p = 0.29]) (Table 3). There
was also no significant heterogeneity in either single cen-
tre studies (χ2 = 4.75, 3 degrees of freedom, p = 0.19) or
multicentre studies (χ2 = 3.84, 2 degrees of freedom, p =
0.15). Moreover, when studies were stratified by Jadad
score, there was no significant reduction in PEP in Jadad
score at 2 or less (IV fixed-effect pooled OR = 1.31 [(95
percent CI 0.70 to 2.46); p = 0.39) or Jadad score at least
3 (IV fixed-effect pooled OR = 1.10 [(95 percent CI 0.85
to 1.43); p = 0.47). There was no significant heterogeneity
in either Jadad score at 2 or less (χ2 = 0.28, 1 degrees of
freedom, p = 0.59) or Jadad score at least 3 (χ2 = 8.11, 4
degrees of freedom, p = 0.09) (Table 3).
Severe PEP was reported in five trials [18,20-23]. These
five trials included 2257 patients with 26 patients suffer-
ing from severe PEP (16 (1.4%) in corticosteroid treat-
ment group and 10 (0.9%) in control group). The Q test
of heterogeneity between studies was not significant (χ2 =
1.34, 3 degree of freedom, p = 0.72). The meta-analysis
did not indicate association between corticosteroid use
and reduction of severe PEP [IV fixed-effect pooled OR
1.61 (95 percent CI 0.74 to 3.52); p = 0.23] (Figure 2,
Table 2). When studies were stratified by setting, there was
no significant reduction in severe PEP in either single cen-
tre studies (IV fixed-effect pooled OR 1.99 (95 percent CI
Effect of corticosteroids in the prophylaxis of post-ERCP pancreatitis Figure 2
Effect of corticosteroids in the prophylaxis of post-ERCP pancreatitis.BMC Gastroenterology 2008, 8:6 http://www.biomedcentral.com/1471-230X/8/6
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0.70 to 5.67); p = 0.20) or multicentre studies (IV fixed-
effect pooled OR 1.21 (95 percent CI 0.37 to 4.00); p =
0.75) (Table 3). There was no significant heterogeneity in
single centre studies (χ2 = 1.12, 2 degrees of freedom, p =
0.57). Only one multicenter study reported severe PEP, so
the result of heterogeneity was unavailable. When strati-
fied by Jadad score, there was no significant reduction in
severe PEP in Jadad score at 2 or less (IV fixed-effect
pooled OR = 1.98 [(95 percent CI 0.62 to 6.34); p = 0.25)
or Jadad score at least 3 (IV fixed-effect pooled OR = 1.35
[(95 percent CI 0.47 to 3.91); p = 0.58). There was no sig-
nificant heterogeneity in either Jadad score at 2 or less (χ2
= 1.12, 1 degrees of freedom, p = 0.29) or Jadad score at
least 3 (χ2 = 0.14, 1 degrees of freedom, p = 0.71) (Table
3).
In addition, case-fatality ratio of PEP in these trials was
extracted with report of case-fatality ratio in three trials
[20-22]. The three trials included 958 patients but with
zero death in corticosteroid group and in placebo group.
So, further evaluation of case-fatality ratio of corticoster-
oid in prophylaxis of PEP is required in the future.
Secondary outcome
Both post-ERCP hyperamylasemia and abdominal pain
were considered as secondary outcome in the report. For
post-ERCP hyperamylasemia, data were derived from two
RCTs [18,22]. These trials included 412 patients with 126
patients suffering from post-ERCP hyperamylasemia.
Among these patients, 61 (29.9%) patients were treated
with corticosteroid and 65 (31.3%) patients with placebo.
The Q test of heterogeneity of effect sizes was not signifi-
cant (χ2 = 0.28, 1 degree of freedom, p = 0.60). Although
the post-ERCP hyperamylasemia was noted in 29.9% of
patients with corticosteroid and 31.3% of control
patients, the results of the meta-analysis indicated no sig-
nificant association between the use of corticosteroid and
reduction of post-ERCP hyperamylasemia [IV fixed-effect
pooled OR 0.92 (95 percent CI 0.57 to 1.48); p = 0.73]
(Figure 2, Table 2). The subgroup analysis of post-ERCP
hyperamylasemia was shown in Table 3.
We were unable to identify any data on post-ERCP
abdominal pain in these trials.
Table 3: Subgroup analysis of the effect of corticosteroid 
prophylaxis of post-ERCP pancreatitis in clinical trials
Heterogeneity
Variable Patients Pooled OR 
(95% CI)
Z p χ2 d.f. p
PEP
Jadad score
≥ 3 2247 1.10 
(0.85, 1.43)
0.72 0.47 8.11 4 0.09
≤ 2 385 1.31 
(0.70, 2.46)
0.85 0.39 0.28 1 0.59
Setting
Single centre 1034 1.04 
(0.66, 1.64)
0.16 0.87 4.75 3 0.19
Multicentre 1598 1.17 
(0.88, 1.56)
1.07 0.29 3.84 2 0.15
Severe PEP
Jadad score
≥ 3 1872 1.35 
(0.47, 3.91)
0.55 0.58 0.14 1 0.71
≤ 2 385 1.98 
(0.62, 6.34)
1.14 0.25 1.12 1 0.29
Setting
Single centre 914 1.99 
(0.70, 5.67)
1.28 0.20 1.12 2 0.57
Multicentre 1343 1.21 
(0.37, 4.00)
0.32 0.75 NA NA NA
Post-ERCP hyperamylasemia
Jadad score
≥ 3 228 0.87 
(0.52, 1.46)
0.53 0.60 NA NA NA
≤ 2 184 1.24 
(0.37, 4.22)
0.35 0.73 NA NA NA
Setting
Single centre 184 1.24 
(0.37, 4.22)
0.35 0.73 NA NA NA
Multicentre 228 0.87 
(0.52, 1.46)
0.53 0.60 NA NA NA
NA = not applicable
Table 2: Sensitivity-analysis of the effect of corticosteroid 
prophylaxis of post-ERCP pancreatitis in clinical trials
Method Patients Pooled OR (95% CI) p
PEP
A 2632 1.13 (0.89, 1.44) 0.32
B 2328 1.20 (0.93, 1.55) 0.17
C 2247 1.10 (0.85, 1.43) 0.47
D 2448 1.13 (0.88, 1.46) 0.34
Severe PEP
A 2257 1.61 (0.74, 3.52) 0.23
B 2073 1.80 (0.68, 4.72) 0.23
C 1872 1.35 (0.47, 3.91) 0.58
D 2073 1.80 (0.68, 4.72) 0.23
Post-ERCP hyperamylasemia
A 412 0.92 (0.57, 1.48) 0.73
B 228 0.87 (0.52, 1.46) 0.60
C 228 0.87 (0.52, 1.46) 0.60
D 228 0.87 (0.52, 1.46) 0.60
A: all included trials [18–24]
B: we excluded the trials that the allocation concealment was 
inadequate or unclear [18, 24]
C: we excluded the trials that the blindness was unadopted [18, 21]
D: we excluded the trials which published in the form of abstract [18]BMC Gastroenterology 2008, 8:6 http://www.biomedcentral.com/1471-230X/8/6
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Sensitivity-analysis
Three different methods were employed to perform sensi-
tivity-analysis of these trials. First, we excluded the trials
that allocation concealment was inadequate or unclear
[18,24]. Second, we excluded the trials that blindness was
not adopted [18,21]. Third, we excluded the trials which
published in abstract [18]. As shown in Table 2, the over-
all estimates were virtually identical and the confidence
intervals were similar between the sensitivity-analysis and
the meta-analysis.
Publication bias
Publication bias was assessed for all pooled ORs with con-
fidence intervals using Begg's test [29,30]. This is a scatter
plot with the treatment effects estimated from individual
studies on horizontal axis (OR) and the standard error of
the estimate on vertical axis (S.E [log OR]). In the Figure
3, all studies were laid within the 95% CI and were uni-
formly distributed around the vertical axis, indicating no
publication bias (Begg's test showed that the p value was
0.133).
Adverse effect
Adverse effects of corticosteroid were evaluated in current
study. We found that three reports indicated different
adverse effects of corticosteroid. In one report [20], there
are 22 patients with adverse effects. 9 patients were in cor-
ticosteroid group and thirteen patients in placebo group.
Patients in corticosteroid group had hemorrhage in four
cases, cholangitis in three cases and acute cholecystis in
two cases. The thirteen patients in the placebo group had
the similar adverse events: hemorrhage in six, cholangitis
in three, acute cholecystis in four cases. In another report
from United States [19], common symptoms such as
abdominal pain, vomiting, and fever or chills were
reported in both groups with no significant difference
between corticosteroid treatment and placebo groups. It
was reported by Sherman et al. [23] that the commonest
adverse effects in corticosteroid group (i.e., nausea, eme-
sis, sweating, and rash) were also observed with similar
frequency in placebo group (5.23% vs. 3.39%, corticoster-
oid and placebo groups respectively; p = 0.14). Therefore,
it was concluded that there was no significant correlation
between the use of corticosteroid and adverse effects.
Discussion
Acute pancreatitis is the most frequent and serious com-
plication of ERCP and affords ample opportunity to eval-
uate potential prophylactic therapy prior to pancreatic
injury. There were several attempts intended to find ther-
apeutic agents to prevent post-ERCP pancreatitis. These
agents include calcitonin, aprotonin, glucogan, somato-
statin, corticosteroid and gabexate mesilate [5-12,21-
24,31-33]. Corticosteroid was proposed to use as prophy-
lactic agent for ERCP due to its anti-inflammatory prop-
erty and autodigestion theory of post-ERCP pancreatitis.
Since the report of Dr. Weiner's retrospective study of ther-
apeutic use of corticosteroid prior to ERCP procedure, sev-
eral prospective randomized clinical trials have been
conducted. Only few studies indicated a beneficial effect
of corticosteroid on prevention of post-ERCP pancreatitis
while most clinical trials did not recommend prophylactic
use of corticosteroid during ERCP procedure. Moreover,
some clinical trials have to be terminated after mid-term
evaluation due to increase in incidence of pancreatitis in
corticosteroid group compared to that of control group
[22,23]. The warrant is due to the report that corticoster-
oid induced pancreatitis in susceptible patients when
administered chronically for non-pancreatic diseases.
However, proof of this causal relationship is limited [34-
36]. On the other hand, it has been reported that corticos-
teroid successfully treat acute pancreatitis [37].
The first study of corticosteroid use in ERCP was con-
ducted in United States in 1995 and the study involved in
patients with oral or intravenous corticosteroid in patients
with iodine-sensitivity to reduce incidence of PEP [17]. In
this report, it was found that corticosteroid was able to
reduce pancreatitis after ERCP as compared to the placebo
(the occurrences of PEP were 4.6% versus 7.4% respec-
tively). The encouraging results of the retrospective survey
of Weiner et al. [17] led to the increasing interest in corti-
costeroid as a promisable pharmacologic agent for pro-
phylactic prevention of PEP. However, except the study of
Kwanngern et al. [24] in 2005, all others studies revealed
a negative conclusion of prophylactic use of corticosteroid
for ERCP [18-23]. Therefore, a meta-analysis is needed to
evaluate publication bias and conclusion of the results.
Current study collected seven RCTs [18-24], which were
published in the world with different languages. The effec-
tiveness and safety of corticosteroid in the prophylaxis of
A funnel plot to explore publication bias Figure 3
A funnel plot to explore publication bias.BMC Gastroenterology 2008, 8:6 http://www.biomedcentral.com/1471-230X/8/6
Page 7 of 8
(page number not for citation purposes)
post-ERCP pancreatitis were evaluated. The meta-analysis
showed that occurrences of PEP [OR = 1.13, 95%CI
(0.89~1.44), p = 0.32], severe PEP [OR = 1.61, 95%CI
(0.74~3.52), p = 0.23], and post-ERCP hyperamylasemia
[OR = 0.92, 95%CI (0.57~1.48), p = 0.73] did not corre-
late with the prophylactic use of corticosteroid. The results
of meta-analysis indicated that corticosteroid could not
prevent pancreatic injury after ERCP. Moreover, a trend
toward higher rates of pancreatitis in corticosteroid
treated group suggested that administration of corticoster-
oid might be hazardous. Furthermore, there was no asso-
ciation between the prophylactic use of corticosteroid and
adverse effects although it was reported in three RCTs
[19,20,23]. The quality of these RCTs was examined
according to the Jadad score [25], and it was found that
the results of meta-analysis were consistent with the sen-
sitivity-analysis. Therefore, there was no publication bias
in these RCTs.
However, what could be the difference among these RCTs
and conclusions? Meta-analysis of these RCTs indicated
that there were differences in experimental design (retro-
spective vs. prospective), forms of corticosteroid (hydro-
cortisone vs. methylprednisolone or prednisone), doses
of corticosteroid (80 mg to 125 mg), routes of administra-
tion (oral administration vs. intravenous injection) and
time of administration (immediate vs. 15, 3 or 1 hour
before ERCP). Retrospective study could be different from
prospective study due to patient recruitment and treat-
ment schedule. In addition, the prospective study indicat-
ing positive recommendation of corticosteroid
application in ERCP had different dose and schedule of
corticosteroid (100 mg hydrocortisone intravenously one
hour before ERCP) [24] than other RCTs that concluded
negative result of corticosteroid use in ERCP (either 120
mg or 100 mg intravenously immediately before ERCP or
40 mg orally 15 and 3 hours before ERCP) [18-23]. There-
fore, further studies with the standard administration of
corticosteroids in ERCP are needed to provide solid evi-
dence regarding its effectiveness in the prevention of post-
ERCP pancreatitis.
Conclusion
In conclusion, the present study shows no statistically sig-
nificant benefit of prophylactic corticosteroid use for pre-
vention of PEP. Therefore, the use of corticosteroids in the
prophylaxis of PEP is not routinely recommended.
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